Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis

DOI: 10.1016/j.tjem.2017.05.007

Keywords: Nivolumab, Immunomodulation, CTLA 4 antigen, Adrenal crisis

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text